Immunogenicity of a single dose mRNA vaccine in SARS-CoV-2 exposed subjects: A systematic review
Dublin Core
Title
Immunogenicity of a single dose mRNA vaccine in SARS-CoV-2 exposed subjects: A systematic review
Creator
Jagtar Singh
Seema Thakur
Date
2022-09-26
Language
en
Type
Journal Article
Zotero
Item Type
Journal Article
ISSN
2522-7165
Abstract Note
Background: The novel coronavirus is quickly spreading and mutating, putting the public health and lifestyle in shambles. The development and approval of mRNA vaccines came up as a breakthrough. The breadth of immune response after a single-dose vaccination in the already infected population is discovered for understanding the hybrid immunity and side effects associated with second dose. Administering a single-dose vaccine to the seropositive population can spare the doses for the population at higher risk.
Methods: PubMed, Web of Science, Google scholar, medRxiv and Cochrane library were explored to extract the original data on the efficacy of single-dose mRNA vaccines in seropositive subjects. The Cochrane risk of bias tool was used to assess the risk of bias in the studies.
Results: 6 studies evaluating the immunogenicity of single-dose mRNA vaccine were incorporated along with some observational studies and literature. These studies present promising evidence for administering only single-dose mRNA vaccine in seropositive subjects, providing biphasic immune response of higher breadth and duration.
Limitations: Most studies had a small sample size, did not correlate the results with higher age groups, with potential risk factors and the percentage of individuals who contracted breakthrough infections.
Conclusions: Single-dose mRNA vaccine can be immunogenic and protective enough for already seropositive population by increasing the number of Spike protein-specific memory B-cells. Vaccination schedules based on existing anti-body titers in such individuals can spare doses for vulnerable groups, especially when there is limited production and supply of vaccines worldwide.
Methods: PubMed, Web of Science, Google scholar, medRxiv and Cochrane library were explored to extract the original data on the efficacy of single-dose mRNA vaccines in seropositive subjects. The Cochrane risk of bias tool was used to assess the risk of bias in the studies.
Results: 6 studies evaluating the immunogenicity of single-dose mRNA vaccine were incorporated along with some observational studies and literature. These studies present promising evidence for administering only single-dose mRNA vaccine in seropositive subjects, providing biphasic immune response of higher breadth and duration.
Limitations: Most studies had a small sample size, did not correlate the results with higher age groups, with potential risk factors and the percentage of individuals who contracted breakthrough infections.
Conclusions: Single-dose mRNA vaccine can be immunogenic and protective enough for already seropositive population by increasing the number of Spike protein-specific memory B-cells. Vaccination schedules based on existing anti-body titers in such individuals can spare doses for vulnerable groups, especially when there is limited production and supply of vaccines worldwide.
Access Date
2023-01-07 23:50:52
Date
2022-09-26
Language
en
Library Catalog
littlebaypublishers.com
Pages
1-13
Publication Title
South East Asia Journal of Medical Sciences
Short Title
Immunogenicity of a single dose mRNA vaccine in SARS-CoV-2 exposed subjects
Title
Immunogenicity of a single dose mRNA vaccine in SARS-CoV-2 exposed subjects: A systematic review
URL
https://littlebaypublishers.com/index.php/seajournalms/article/view/85
Attachment Title
Full Text PDF
Files
Collection
Citation
Jagtar Singh and Seema Thakur, “Immunogenicity of a single dose mRNA vaccine in SARS-CoV-2 exposed subjects: A systematic review,” Open Access Journal Archives, accessed March 22, 2023, https://www.oajour.info/items/show/1844.